Wissenschaftl. Titel | Breaking the big Five Barriers of Brain Metastasis (Break B5-BM NSCLC Trial): A prospective phase II, open-label, multi-center trial of combined nivolumab, ipilimumab and bevacizumab together with 2 cycles of induction chemotherapy in patients with non-squamous non-small-cell lung cancer (NSCLC) metastatic to the brain |
Erkrankung |
Thorax:
Nicht-kleinzelliges Lungenkarzinom:
Erstlinie
|
Kurzprotokoll | Kurzprotokoll |
Links | Weiterführende Informationen (O) Weiterführende Informationen (EudraCT) |
erstellt 30.05.2022 Data entry I CCP
geändert 10.10.2022 Data entry III CCP